abstract |
The technical problem inherent in the present invention is to provide an improved vaccine that prevents EHV infection better than prior art vaccines. The present invention relates to the field of animal health, in particular the equine herpesvirus (EHV), which lacks the heterologous element without the gene encoding the protein gM. A further aspect of the present invention relates to a pharmaceutical composition comprising said virus, its use, and a method for preventing and treating EHV infection. The present invention also relates to a pharmaceutical composition comprising a combination of EHV-1 and EHV-4 viruses that lack the gene encoding protein gM and are free of heterologous elements. [Selection] Figure 1 |